Total Payments
$380,489
2024 Payments
$225,721
Companies
27
Transactions
77
Medicare Patients
3,842
Medicare Billing
$618,162
Payment Breakdown by Category
Research$354,541 (93.2%)
Consulting$19,550 (5.1%)
Food & Beverage$2,792 (0.7%)
Travel$2,630 (0.7%)
Other$706.57 (0.2%)
Education$269.73 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $354,541 | 22 | 93.2% |
| Consulting Fee | $19,550 | 3 | 5.1% |
| Food and Beverage | $2,792 | 33 | 0.7% |
| Travel and Lodging | $2,630 | 8 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $706.57 | 2 | 0.2% |
| Education | $269.73 | 9 | 0.1% |
Payments by Type
Research
$354,541
22 transactions
General
$25,948
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IGI Inc | $225,596 | 7 | $0 (2024) |
| Ichnos Sciences Inc. | $123,567 | 6 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $9,918 | 5 | $0 (2017) |
| Astellas Pharma US Inc | $7,556 | 4 | $0 (2019) |
| Amgen Inc. | $5,224 | 8 | $0 (2022) |
| PFIZER INC. | $2,218 | 5 | $0 (2022) |
| F. Hoffmann-La Roche AG | $1,771 | 4 | $0 (2020) |
| Celgene Corporation | $1,417 | 5 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $889.24 | 2 | $0 (2020) |
| Incyte Corporation | $485.60 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $225,721 | 8 | IGI Inc ($225,596) |
| 2023 | $124,070 | 11 | Ichnos Sciences Inc. ($123,567) |
| 2022 | $1,493 | 6 | PFIZER INC. ($940.00) |
| 2021 | $1,441 | 7 | PFIZER INC. ($1,270) |
| 2020 | $2,561 | 10 | F. Hoffmann-La Roche AG ($1,065) |
| 2019 | $14,492 | 17 | Astellas Pharma US Inc ($7,556) |
| 2018 | $630.68 | 7 | F. Hoffmann-La Roche AG ($370.42) |
| 2017 | $10,080 | 11 | Bayer HealthCare Pharmaceuticals Inc. ($9,918) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $119,980.00 | Research |
| Study: ISB 1342-101 | ||||||
| 09/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $77,457.00 | Research |
| Study: ISB 1342-101 | ||||||
| 07/31/2024 | IGI Inc | — | — | Cash or cash equivalent | $5,957.00 | Research |
| Study: ISB 1342-101 | ||||||
| 05/24/2024 | IGI Inc | — | — | Cash or cash equivalent | $5,105.00 | Research |
| Study: ISB 1342-101 | ||||||
| 05/24/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,756.93 | Research |
| Study: ISB 1342-101 | ||||||
| 05/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 04/03/2024 | IGI Inc | — | — | Cash or cash equivalent | $4,133.65 | Research |
| Study: ISB 1342-101 | ||||||
| 01/19/2024 | IGI Inc | — | — | Cash or cash equivalent | $10,206.00 | Research |
| Study: ISB 1342-101 | ||||||
| 11/14/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $571.00 | Research |
| Study: ISB 1342-101 | ||||||
| 11/14/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $111.81 | General |
| Category: Oncology | ||||||
| 10/03/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $24,161.00 | Research |
| Study: ISB 1342-101 | ||||||
| 09/14/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $124.74 | General |
| 09/12/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $536.00 | Research |
| Study: ISB 1342-101 | ||||||
| 08/17/2023 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $121.86 | General |
| Category: Oncology | ||||||
| 08/10/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 07/25/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $64,862.00 | Research |
| Study: ISB 1342-101 | ||||||
| 03/14/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $31,752.00 | Research |
| Study: ISB 1342-101 | ||||||
| 01/10/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $1,685.00 | Research |
| Study: ISB 1342-101 | ||||||
| 12/08/2022 | Amgen Inc. | — | Education | In-kind items and services | $99.00 | General |
| 10/28/2022 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 09/14/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $108.50 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2022 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $121.12 | General |
| Category: Hematology/Oncology | ||||||
| 05/17/2022 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: TRILLIUM CLINICAL PUBLICATION PROGRAM | ||||||
| 03/04/2022 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $99.54 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | IGI Inc | $225,596 | 7 |
| ISB 1342-101 | Ichnos Sciences Inc. | $123,567 | 6 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001), A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL & OUTREACH 3L+ LBCL 017007 (017001, 017006, 017007) | Celgene Corporation | $1,144 | 1 |
| A PHASE IBII STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $1,065 | 2 |
| TRILLIUM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| REGN1979-CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $889.24 | 2 |
| A Phase 1 2 Open label Randomized Study of Ulocuplumab BMS 936564 In Combination with Low Dose Cytarabine in Subjects with Newly Diagnosed Acute Myeloid Leukemia | E.R. Squibb & Sons, L.L.C. | $70.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 934 | 2,150 | $516,852 | $149,911 |
| 2022 | 10 | 970 | 2,083 | $508,977 | $148,120 |
| 2021 | 12 | 981 | 2,392 | $616,567 | $182,672 |
| 2020 | 13 | 957 | 2,183 | $536,395 | $137,459 |
Total Patients
3,842
Total Services
8,808
Medicare Billing
$618,162
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 310 | 1,056 | $242,674 | $74,054 | 30.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 72 | 343 | $72,382 | $20,269 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 107 | 152 | $49,240 | $16,209 | 32.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 243 | 336 | $49,882 | $14,946 | 30.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 85 | $50,328 | $11,083 | 22.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 38 | 63 | $19,687 | $5,311 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 31 | 31 | $15,369 | $3,929 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 19 | 19 | $7,277 | $1,374 | 18.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 38 | 43 | $3,182 | $1,084 | 34.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $4,378 | $1,025 | 23.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 11 | 11 | $2,453 | $627.60 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 364 | 1,099 | $251,671 | $76,119 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 58 | 226 | $68,704 | $17,526 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 257 | 355 | $52,540 | $16,632 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 100 | 159 | $51,357 | $16,253 | 31.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 46 | 62 | $36,580 | $8,980 | 24.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $12,275 | $3,443 | 28.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 31 | 40 | $12,440 | $3,183 | 25.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 33 | 55 | $11,550 | $2,993 | 25.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 24 | 24 | $9,048 | $2,016 | 22.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 32 | 38 | $2,812 | $972.86 | 34.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 309 | 1,053 | $241,137 | $74,876 | 31.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 75 | 402 | $122,208 | $31,663 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 127 | 272 | $87,856 | $30,239 | 34.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 231 | 337 | $49,876 | $15,546 | 31.2% |
About Dr. Don Stevens, M.D
Dr. Don Stevens, M.D is a Medical Oncology healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952369621.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Don Stevens, M.D has received a total of $380,489 in payments from pharmaceutical and medical device companies, with $225,721 received in 2024. These payments were reported across 77 transactions from 27 companies. The most common payment nature is "" ($354,541).
As a Medicare-enrolled provider, Stevens has provided services to 3,842 Medicare beneficiaries, totaling 8,808 services with total Medicare billing of $618,162. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Louisville, KY
- Active Since 05/03/2006
- Last Updated 03/07/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1952369621
Products in Payments
- Non-Covered $9,918
- JCAR017 (Drug) $1,144
- Non-Covered Product (Drug) $1,065
- Kyprolis (Biological) $712.01
- GAZYVA (Biological) $706.57
- JAKAFI (Drug) $360.86
- XPOVIO (Drug) $258.93
- Revlimid (Drug) $153.27
- CRESEMBA (Drug) $131.24
- BRUKINSA (Drug) $125.00
- VENCLEXTA (Drug) $124.99
- MONJUVI (Drug) $124.74
- Yescarta (Drug) $124.27
- RYBREVANT (Drug) $121.86
- ONUREG (Drug) $120.19
- ADCETRIS (Biological) $111.96
- Tazverik (Drug) $111.81
- ENHERTU (Drug) $108.50
- VERZENIO (Drug) $91.97
- SANCUSO (Drug) $50.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Louisville
Kenneth Hodge, Md, MD
Medical Oncology — Payments: $104,641
Medical Oncology $104,641
Dr. John Hamm, M.d, M.D
Medical Oncology — Payments: $40,642
Medical Oncology $40,642
Dr. Renato Larocca, M.d, M.D
Medical Oncology — Payments: $32,819
Medical Oncology $32,819
Michael Driscoll, M.d, M.D
Medical Oncology — Payments: $2,626
Medical Oncology $2,626
Dr. Subhash Sheth, Md, MD
Medical Oncology — Payments: $1,553
Medical Oncology $1,553
Dr. Sheron Williams, Md, MD
Medical Oncology — Payments: $332.49
Medical Oncology $332.49